

## Actemra® (tocilizumab) – Updated labeling

- On February 28, 2022, the <u>FDA approved</u> Genentech's intravenous (IV) formulation of <u>Actemra</u> (tocilizumab), for treatment of giant cell arteritis (GCA) in adult patients.
  - Previously, only the subcutaneous (SC) formulation of Actemra was approved for this indication.
- The IV and SC formulations of Actemra are also approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
- Additionally, the SC formulation of Actemra is approved for systemic sclerosis-associated interstitial lung disease and the IV formulation is approved for cytokine release syndrome.
- Actemra carries a boxed warning for risk of serious infections.
- The recommended IV dose of Actemra for the treatment of GCA is a 60-minute single IV drip infusion of 6 mg/kg every 4 weeks in combination with a tapering course of glucocorticoids.
  - Actemra can be used alone following discontinuation of glucocorticoids. Doses exceeding 600 mg per infusion are not recommended in GCA patients.
  - Refer to the Actemra drug label for dosing for all its other indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.